Evaluating the reactogenicity of COVID-19 vaccines from network-meta analyses

Giorgia Tiozzo*, Timon Louwsma, Stefan R.A. Konings, Gerard T. Vondeling, Judith Perez Gomez, Maarten J. Postma, Roel D. Freriks

*Bijbehorende auteur voor dit werk

OnderzoeksoutputAcademicpeer review

1 Citaat (Scopus)
22 Downloads (Pure)

Samenvatting

Background: Evidence-based reassurances addressing vaccine-related concerns are crucial to promoting primary vaccination, completion of the primary series, and booster vaccination. By summarizing and comparing the reactogenicity of COVID-19 vaccines authorized by the European Medicines Agency, this analysis aims to support in-formed decision-making by the lay public and help overcome vaccine hesitancy. 

Research design and methods: A systematic literature review identified 24 records reporting solicited adverse events for AZD1222, BNT162b2, mRNA-1273, NVX-Cov2373, and VLA2001 in individuals aged 16 or older. Network meta-analyses were conducted for each solicited adverse events reported for at least two vaccines that were not compared head-to-head but could be connected through a common comparator. 

Results: A total of 56 adverse events were investigated through network meta-analyses within a Bayesian framework with random-effects models. Overall, the two mRNA vaccines were found to be the most reactogenic vaccines. VLA2001 had the highest likelihood of being the least reactogenic vaccine after the first and second vaccine dose, especially for systemic adverse events after the first dose. 

Conclusions: The reduced chance of experiencing an adverse event with some COVID-19 vaccines may help to overcome vaccine hesitancy in population groups with concerns about the side effects of vaccines.

Originele taal-2English
Pagina's (van-tot)410-418
Aantal pagina's9
TijdschriftExpert review of vaccines
Volume22
Nummer van het tijdschrift1
DOI's
StatusPublished - 2023

Citeer dit